Literature DB >> 32499241

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.

Jason P Cooper1, Barry E Storer1, Noa Granot2, Boglark Gyurkocza1, Mohamed L Sorror1, Thomas R Chauncey3, Judith Shizuru4, Georg-Nikolaus Franke5, Michael B Maris6, Michael Boyer7, Benedetto Bruno8, Firoozeh Sahebi9, Amelia A Langston10, Parameswaran Hari11, Edward D Agura12, Søren Lykke Petersen13, Richard T Maziarz14, Wolfgang Bethge15, Julie Asch16, Jonathan A Gutman17, Gitte Olesen18, Andrew M Yeager19, Kai Hübel20, William J Hogan21, David G Maloney1, Marco Mielcarek1, Paul J Martin1, Mary E D Flowers1, George E Georges1, Ann E Woolfrey1, Joachim H Deeg1, Bart L Scott1, George B McDonald1, Rainer Storb1, Brenda M Sandmaier1.   

Abstract

We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past twenty years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypothesized that improvements in clinical practice led to better transplantation outcomes over time. From 1997-2017, 1,720 patients with hematologic malignancies received low-dose total body irradiation +/- fludarabine or clofarabine before transplantation from HLA-matched sibling or unrelated donors, followed by mycophenolate mofetil and a calcineurin inhibitor ± sirolimus. We compared outcomes in three cohorts by year of transplantation: 1997 +/- 2003 (n=562), 2004 +/- 2009 (n=594), and 2010 +/- 2017 (n=564). The proportion of patients ≥60 years old increased from 27% in 1997 +/- 2003 to 56% in 2010-2017, and with scores from the Hematopoietic Cell Transplantation Comborbidity Index of ≥3 increased from 25% in 1997 +/- 2003 to 45% in 2010 +/- 2017. Use of unrelated donors increased from 34% in 1997 +/- 2003 to 65% in 2010-2017. When outcomes from 2004 +/- 2009 and 2010-2017 were compared to 1997 +/- 2003, improvements were noted in overall survival (P=.0001 for 2004-2009 and P <.0001 for 2010-2017), profression-free survival (P=.002 for 2004-2009 and P <.0001 for 2010 +/- 2017), non-relapse mortality (P<.0001 for 2004 +/- 2009 and P <.0001 for 2010 +/- 2017), and in rates of grades 2 +/- 4 acute and chronic graft-vs.-host disease. For patients with hematologic malignancies who underwent transplantation with non-myeloablative conditioning, outcomes have improved during the past two decades. Trials reported are registered under ClinicalTrials.gov identifiers: NCT00003145, NCT00003196, NCT00003954, NCT00005799, NCT00005801, NCT00005803, NCT00006251, NCT00014235, NCT00027820, NCT00031655, NCT00036738, NCT00045435, NCT00052546, NCT00060424, NCT00075478, NCT00078858, NCT00089011, NCT00104858, NCT00105001, NCT00110058, NCT00397813, NCT00793572, NCT01231412, NCT01252667, NCT01527045.

Entities:  

Year:  2021        PMID: 32499241     DOI: 10.3324/haematol.2020.248187

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  5 in total

1.  External Validation of the Revised Pretransplant Assessment of Mortality Score in Allogeneic Hematopoietic Cell Transplantation: A Cohort Study.

Authors:  Nicolas Fattinger; Jan A Roth; Helen Baldomero; Daiana Stolz; Michael Medinger; Dominik Heim; Michael Tamm; Jörg P Halter; Jakob R Passweg; Martina Kleber
Journal:  Hemasphere       Date:  2022-03-11

2.  Editorial: Strengths and Challenges of Allo-SCT in the Modern Era.

Authors:  Michele Malagola; Raffaella Greco; Jacopo Peccatori; Alessandro Isidori; Rizwan Romee; Mohamad Mohty; Fabio Ciceri; Domenico Russo
Journal:  Front Oncol       Date:  2022-02-24       Impact factor: 6.244

Review 3.  Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.

Authors:  Akihiro Ohmoto; Shigeo Fuji; Kendall C Shultes; Bipin N Savani; Hermann Einsele
Journal:  Bone Marrow Transplant       Date:  2022-04-19       Impact factor: 5.174

4.  Twenty years of experience of a tertiary cancer center in total body irradiation with focus on oncological outcome and secondary malignancies.

Authors:  Katharina Sieker; Maximilian Fleischmann; Martin Trommel; Ulla Ramm; Jörg Licher; Gesine Bug; Hans Martin; Hubert Serve; Claus Rödel; Panagiotis Balermpas
Journal:  Strahlenther Onkol       Date:  2022-03-22       Impact factor: 4.033

5.  Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Authors:  Lucas C Zarling; Megan Othus; Brenda M Sandmaier; Filippo Milano; Gary Schoch; Chris Davis; Marie Bleakley; H Joachim Deeg; Frederick R Appelbaum; Rainer Storb; Roland B Walter
Journal:  Leukemia       Date:  2022-04-19       Impact factor: 12.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.